Pergolide increases the efficacy of cathodal direct current stimulation to reduce the amplitude of laser-evoked potentials in humans.
Pergolide increases the efficacy of cathodal direct current stimulation to reduce the amplitude of laser-evoked potentials in humans.
复制标题
DOI：
10.1016/j.jpainsymman.2007.08.014
复制
发表时间：
2008-07
影响因子：
4.7
通讯作者：
D. Terney;Inga Bergmann;C. Poreisz;L. Chaieb;K. Boros;M. Nitsche;W. Paulus;A. Antal
中科院分区：
文献类型：
--
作者：
D. Terney;Inga Bergmann;C. Poreisz;L. Chaieb;K. Boros;M. Nitsche;W. Paulus;A. Antal
经颅直流电刺激（tDCS）最近被重新引入，作为一种工具，在局灶脑区诱导相对持久的皮层兴奋性变化。初级运动皮层的阳极刺激增强了皮层的兴奋性，而阴极刺激则降低了它。先前的研究表明，培高利特增强D2受体活性可巩固tdcs产生的兴奋性减弱长达24小时，初级运动皮层的阴极刺激可减弱实验诱导的痛觉，并降低刺激后立即激光诱发电位的N2-P2振幅。在本研究中，我们通过双盲、随机、安慰剂对照、交叉研究，研究了佩高利特和初级运动皮层阴极tDCS对Tm:YAG激光诱发电位和急性疼痛感知的影响。分析了12名健康受试者联合培高利特或安慰剂进行15分钟阴极tDCS前后5个不同时间点的激光诱发电位振幅变化和主观疼痛评分。我们的结果表明，在阴极tDCS长达两小时后，N2组分的振幅显着降低。此外，培高利特延长了阴极tDCS的效果长达24小时，并且观察到疼痛感觉显著降低长达40分钟。我们的研究是在初级运动皮层上应用阴极tDCS的临床应用的进一步一步，通过药物干预延长刺激后24小时对疼痛感知的兴奋性降低效应。此外，它显示了对疼痛患者进行重复性每日刺激治疗的潜力。
Transcranial direct current stimulation (tDCS) was recently reintroduced as a tool for inducing relatively long-lasting changes in cortical excitability in focal brain regions. Anodal stimulation over the primary motor cortex enhances cortical excitability, whereas cathodal stimulation decreases it. Prior studies have shown that enhancement of D2 receptor activity by pergolide consolidates tDCS-generated excitability diminution for up to 24 hours and that cathodal stimulation of the primary motor cortex diminishes experimentally induced pain sensation and reduces the N2–P2 amplitude of laser-evoked potentials immediately poststimulation. In the present study, we investigated the effect of pergolide and cathodal tDCS over the primary motor cortex on laser-evoked potentials and acute pain perception induced with a Tm:YAG laser in a double-blind, randomized, placebo-controlled, cross-over study. The amplitude changes of laser-evoked potentials and subjective pain rating scores of 12 healthy subjects were analyzed prior to and following 15 minutes cathodal tDCS combined with pergolide or placebo intake at five different time points. Our results indicate that the amplitude of the N2 component was significantly reduced following cathodal tDCS for up to two hours. Additionally, pergolide prolonged the effect of the cathodal tDCS for up to 24 hours, and a significantly lowered pain sensation was observed for up to 40minutes. Our study is a further step toward clinical application of cathodal tDCS over the primary motor cortex using pharmacological intervention to prolong the excitability-diminishing effect on pain perception for up to 24 hours poststimulation. Furthermore, it demonstrates the potential for repetitive daily stimulation therapy for pain patients.